0000950170-24-041426.txt : 20240403 0000950170-24-041426.hdr.sgml : 20240403 20240403193335 ACCESSION NUMBER: 0000950170-24-041426 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ciaramella Giuseppe CENTRAL INDEX KEY: 0001786322 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39208 FILM NUMBER: 24820958 MAIL ADDRESS: STREET 1: C/O BEAM THERAPEUTICS INC. STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Beam Therapeutics Inc. CENTRAL INDEX KEY: 0001745999 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-327-8775 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 ownership.xml 4 X0508 4 2024-04-01 0001745999 Beam Therapeutics Inc. BEAM 0001786322 Ciaramella Giuseppe C/O BEAM THERAPEUTICS INC., 238 MAIN STREET CAMBRIDGE MA 02142 false true false false President true Common Stock 2024-04-01 4 S false 4534 32.12 D 169616 D Stock Option (Right to Buy) 0.67 2024-04-03 4 A false 27318 0.00 A 2024-04-03 2028-05-08 Common Stock 27318 27318 D Stock Option (Right to Buy) 4.22 2024-04-03 4 A false 12979 0.00 A 2024-04-03 2029-02-13 Common Stock 12979 12979 D These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.09 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. On May 8, 2018, the Reporting Person was granted an option to purchase 27,318 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 27,318 shares. On February 13, 2019, the Reporting Person was granted an option to purchase 12,979 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 12,979 shares. By: /s/ Christine Bellon, Attorney-in-fact 2024-04-03